M&A: Buckle your seat belts for another big round of deals

John Carroll

With valuations down, buyouts and licensing become even more attractive. They're already a requirement. Anyone with a casual acquaintance with the state of Big Pharma R&D knows the giants in this business badly need promising mid- and late-stage assets to feed into their pipelines.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS